XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW043B7
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW043B7 is a billable ICD-10-PCS procedure code for Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code
XW043B7
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
Parent Code
XW0
Short Description
Introduce Amivantamab in Central Vein, Perc, New Tech 7

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyBAmivantamab Monoclonal Antibody
7Qualifier7New Technology Group 7

Code History

Replaces previously assigned code(s):
  • 3E0430M — Introduce Monoclonal Antibody in Central Vein, Perc

Similar Procedure Codes

Questions About XW043B7

Is XW043B7 a billable code?

Yes. XW043B7 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW043B7 mean?

XW043B7 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character B is the Device/Substance/Technology (Amivantamab Monoclonal Antibody); the 7th character 7 is the Qualifier (New Technology Group 7).